ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0170

Utilizing Design Thinking to Develop a Decision Aid for Patients with Psoriasis and Psoriatic Arthritis

Marilyn Wan1, Michele Almonte2, Joel Gelfand1 and Alexis Ogdie2, 1University of Pennsylvania, Philadelphia, 2University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2020

Keywords: Dermatology, Psoriatic arthritis, Qualitative Research

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Given the complexity of available treatment recommendations, patients with psoriatic disease would benefit from a process fostering shared decision-making using a patient-centered approach. True shared decision-making is challenging during short visits but patient decision aids (DAs) can assist this. This study aimed to understand patient and clinician needs in the process of starting/switching therapy and use design thinking to develop a patient-centered DA that addresses these needs.

Methods: Design thinking, a method adopted from engineering, first seeks to understand user needs to develop a prototype which is then iteratively revised based on user input. Semi-structured interviews of ten patients and two focus groups with rheumatologists (n=7), dermatologists (including one nurse practitioner) (n=5) and specialty pharmacists (n=2) were conducted to inform the first prototype. Follow-up focus groups with the same healthcare providers and semi-structured interviews with an additional eight patients were conducted to revise the prototype. Interview transcripts were independently coded by two research team members using NVivo12 to elicit pertinent themes. Participants were continually interviewed until saturation of themes was reached where no new themes emerged.

Results: Themes were identified from clinicians and patients (representative quotes in Table 1). Interrater reliability of the two coders surpassed the a priori kappa threshold of 0.80 to ensure consistency in coding. Clinicians felt that a DA was most useful for patients initiating or switching therapies and should include basic information about the disease, managing flares, and individual therapies. Clinicians suggested that treatment options should be identified using an algorithm that considers patient characteristics (e.g., comorbidities) and then select 2-3 therapies for patients to learn about. Patients desired a DA that would give them access to all information about therapies including lifestyle alterations from medications, efficacy rates, side effects, insurance coverage, and personal testimonials from other patients. Patients and clinicians noted readability and easy navigation as necessary. Patients desired more detailed information than anticipated by clinicians or would typically be provided in a short encounter. The final decision aid prototype can be found at psoriasisdecisionaid.com.

Conclusion: Design thinking was an effective method of creating a comprehensive decision aid; including patients, clinicians and pharmacists was of critical importance in arriving at a final decision aid that serves the needs of all stakeholders. Next steps include testing how the decision impacts treatment decisions and whether it reduces decision conflict.

Table 1. Themes identified and representative quotes.


Disclosure: M. Wan, None; M. Almonte, Amgen Inc., 9; J. Gelfand, Bristol-Myers Squibb, 5, Boehringer Ingelheim, 5, GlaxoSmithKline, 5, Janssen Biologics, 2, 5, Novartis Corp, 2, 5, Regeneron, 5, UCB, 9, Sanofi, 2, 5, Pfizer Inc, 2, 5, Abbvie, 2, Celgene, 2, Ortho Dermatologics, 2, 9, Eli Lilly and Company, 9, Journal of Investigative Dermatology, 9, Society for Investigative Dermatology, 8, Spirig Pharma, 9; A. Ogdie, abbvie, 1, amgen, 1, bms, 1, celgene, 1, corona, 1, lilly, 1, janssen, 1, novartis, 1, 2, novartis, 1, pfizer, 1.

To cite this abstract in AMA style:

Wan M, Almonte M, Gelfand J, Ogdie A. Utilizing Design Thinking to Develop a Decision Aid for Patients with Psoriasis and Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/utilizing-design-thinking-to-develop-a-decision-aid-for-patients-with-psoriasis-and-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utilizing-design-thinking-to-develop-a-decision-aid-for-patients-with-psoriasis-and-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology